Vered Stearns
YOU?
Author Swipe
View article: Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index Open
Importance The Breast Cancer Index (BCI) previously identified premenopausal patients with tumors in which the ratio of expression of HOXB13 relative to IL17BR (hereafter, BCI [H/I]–low tumors) as likely to derive greatest benefit from ova…
View article: 735 T cell interactions and B cell activation mediate response to treatment with entinostat and checkpoint inhibitors in metastatic breast cancer
735 T cell interactions and B cell activation mediate response to treatment with entinostat and checkpoint inhibitors in metastatic breast cancer Open
View article: MMAP-07 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH ALPELISIB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
MMAP-07 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH ALPELISIB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS Open
BACKGROUND Alpelisib is FDA-approved for patients with HR-positive, HER-2 negative, PIK3CA-mutated metastatic breast cancer with progression on/after receiving endocrine therapy. We investigated the CNS progression patterns of patients on …
View article: MMAP-08 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH SACITUZUMAB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
MMAP-08 CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH SACITUZUMAB: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS Open
BACKGROUND Sacituzumab is FDA approved for unresectable locally advanced or metastatic triple-negative or HR-positive/HER2-negative breast cancer in the metastatic setting. Sacituzumab’s ability to prevent or control CNS disease is not yet…
View article: Cancer systems immunology reveals myeloid—T cell interactions and B cell activation mediate response to checkpoint inhibition in metastatic breast cancer
Cancer systems immunology reveals myeloid—T cell interactions and B cell activation mediate response to checkpoint inhibition in metastatic breast cancer Open
Sensitization of the immune-suppressed tumor microenvironment (TME) of breast cancer by histone deacetylase inhibition shows promise, but the mechanisms of sensitization are unknown. We investigated the TME of breast-to-lung metastases by …
View article: Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab
Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab Open
View article: A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026) Open
The HER2/PET-CT biomarker had high prediction power for pCR, however was not superior to the prediction power of PET/CT alone. Non-invasive PET/CT biomarkers may facilitate a response-guided approach to neoadjuvant therapy, allowing intens…
View article: The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen Open
View article: 555 Anti-tumor activity of Treg-depleting therapy depending on the tumor glycolytic capacity
555 Anti-tumor activity of Treg-depleting therapy depending on the tumor glycolytic capacity Open
View article: CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108 Open
View article: Supplementary Figure Legends from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Supplementary Figure Legends from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
Supplementary Figure Legends for Fig. S1-S4
View article: Figure S3 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Figure S3 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
PFS KM curves
View article: Supplementary Tables from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Supplementary Tables from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
Supplementary Tables S1-S5
View article: Figure S4 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Figure S4 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
Molecular characteristics of BRCA reversion mutations
View article: Figure S1 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Figure S1 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
BROCADE3 study design
View article: Data from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Data from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
Purpose:Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who recei…
View article: Figure S2 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
Figure S2 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover) Open
CONSORT diagram
View article: Data from RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Data from RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer Open
Purpose:While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features …
View article: Supplementary Data from RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Supplementary Data from RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer Open
Supplementary Figures S1-S7. Supplementary Tables S1-S4
View article: Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion Open
Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.
View article: Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S5: Association between clinicopathological variables and treatment discontinuation due to AIMSS.
View article: Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Purpose:Aromatase inhibitor (AI)–associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohor…
View article: Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S4: HAQ Scores at different time points (n=970).
View article: Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S6: Allele frequency and Hardy-Weinberg equilibrium test result, by patient cohort.
View article: Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S5: Association between clinicopathological variables and treatment discontinuation due to AIMSS.
View article: Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S3: Off Treatment Reason.
View article: Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S3: Off Treatment Reason.
View article: Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S6: Allele frequency and Hardy-Weinberg equilibrium test result, by patient cohort.
View article: Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S1: Representativeness of Study Participants
View article: Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).